+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

How to successfully audit software systems, and thereby avoid having FDA write software-related 483's and warning letters

  • Training

  • 60 Minutes
  • Compliance Online
  • ID: 5975884
This Software Auditing Procedure training will discussion on FDA software Standard “General Principles of Software Validation”, Actual FDA investigator software auditing techniques for software failure investigations.

Why Should You Attend:

Many companies are confident that their software system is compliant to the Quality System Regulation, yet FDA conducts an inspection and FDA 483 software related cites are written and warning Letters, seizures or worse ensue. This presentation will review the FDA Software Standard “General Principles of Software Validation'. Understanding this guidance is vital for compliance and for regulatory submission success. We will address Real auditing processes and risk management tools relative to this standard. The process that FDA investigators use relative to software failure investigations will also be discussed. Real auditing processes and risk management tools will be discussed.

Learning Objectives:

  • What FDA expects and will request from you during your software review.
  • Learn how QSIT inspections related to software systems and its attendant record keeping are performed by FDA.
  • Learn how change control issues affect software records.
  • Learn what constitutes a good software auditing procedure.
  • Learn how do how to counteract a possible FDA 483 cite.
  • How risk management fits into software compliance.
  • Learn how to incorporate the FDA “General Principles of Software Validation' document into your quality system.

Areas Covered in the Seminar:

  • Introduction.
  • Guidance documents/QS regulation.
  • Major FDA 483 points.
  • Trends in FDA warning letters.
  • Determining best practice for the software audit.
  • Conducting a MORE thorough audit.
  • FDA 483 point issuance prevention.
  • Questions & Answers.

Who Will Benefit:

The following individuals or disciplines will benefit from attending this Webinar:
  • Senior executives of pharmaceutical and device firms
  • Quality Unit Vice Presidents, Directors and Managers
  • Vice presidents, Directors and Managers of operations
  • Quality engineers and field auditors
  • Regulatory and Compliance Management
  • Consultants
  • Quality System Auditors

Course Provider

  • Dennis Moore
  • Dennis Moore,